{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:27:45Z","timestamp":1789525665994,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genetic lesions of <jats:italic>IKZF1<\/jats:italic> are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found <jats:italic>IKZF1<\/jats:italic> alterations in 45 cases with a mutational hotspot at N159S. AML with mutated <jats:italic>IKZF1<\/jats:italic> was associated with alterations in <jats:italic>RUNX1<\/jats:italic>, <jats:italic>GATA2<\/jats:italic>, <jats:italic>KRAS<\/jats:italic>, <jats:italic>KIT<\/jats:italic>, <jats:italic>SF3B1<\/jats:italic>, and <jats:italic>ETV6<\/jats:italic>, while alterations of <jats:italic>NPM1<\/jats:italic>, <jats:italic>TET2<\/jats:italic>, <jats:italic>FLT3<\/jats:italic>-ITD, and normal karyotypes were less frequent. The clinical phenotype of <jats:italic>IKZF1<\/jats:italic>-mutated AML was dominated by anemia and thrombocytopenia. In both univariable and multivariable analyses adjusting for age, de novo and secondary AML, and ELN2022 risk categories, we found mutated <jats:italic>IKZF1<\/jats:italic> to be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival. The deleterious effects of mutated <jats:italic>IKZF1<\/jats:italic> also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (<jats:italic>n<\/jats:italic>\u2009=\u2009519) in both univariable and multivariable models. These dismal outcomes are only partially explained by the hotspot mutation N159S. Our findings suggest a role for <jats:italic>IKZF1<\/jats:italic> mutation status in AML risk modeling.<\/jats:p>","DOI":"10.1038\/s41375-023-02061-1","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T19:01:32Z","timestamp":1697223692000},"page":"2395-2403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-2823","authenticated-orcid":false,"given":"Jan-Niklas","family":"Eckardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-4894","authenticated-orcid":false,"given":"Sebastian","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6693-4079","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Kunzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-8940","authenticated-orcid":false,"given":"Maher","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"R\u00e1cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Oelschl\u00e4gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-5516","authenticated-orcid":false,"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-8371","authenticated-orcid":false,"given":"Andreas","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"2061_CR1","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","DOI":"10.1182\/blood.2022016867"},{"key":"2061_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","volume":"48","author":"LB John","year":"2011","unstructured":"John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. 2011;48:1272\u20138.","journal-title":"Mol Immunol"},{"key":"2061_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4049\/jimmunol.156.2.585","volume":"156","author":"A Moln\u00e1r","year":"1996","unstructured":"Moln\u00e1r A, Wu P, Largespada DA, Vortkamp A, Scherer S, Copeland NG, et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. J Immunol. 1996;156:585\u201392.","journal-title":"J Immunol"},{"key":"2061_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4331\/wjbc.v2.i6.161","volume":"2","author":"MA Payne","year":"2011","unstructured":"Payne MA. Zinc finger structure-function in Ikaros. World J Biol Chem. 2011;2:161\u20136.","journal-title":"World J Biol Chem"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/emboj\/cdg186","volume":"22","author":"C Kaufmann","year":"2003","unstructured":"Kaufmann C, Yoshida T, Perotti EA, Landhuis E, Wu P, Georgopoulos K. A complex network of regulatory elements in Ikaros and their activity during hemo-lymphopoiesis. EMBO J. 2003;22:2211\u201323.","journal-title":"EMBO J"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1126\/science.1439790","volume":"258","author":"K Georgopoulos","year":"1992","unstructured":"Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science. 1992;258:808\u201312.","journal-title":"Science"},{"key":"2061_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","volume":"79","author":"K Georgopoulos","year":"1994","unstructured":"Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994;79:143\u201356.","journal-title":"Cell"},{"key":"2061_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0092-8674(95)90170-1","volume":"83","author":"S Winandy","year":"1995","unstructured":"Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995;83:289\u201399.","journal-title":"Cell"},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1101\/sqb.1999.64.79","volume":"64","author":"J Koipally","year":"1999","unstructured":"Koipally J, Kim J, Jones B, Jackson A, Avitahl N, Winandy S, et al. Ikaros chromatin remodeling complexes in the control of differentiation of the hemo-lymphoid system. Cold Spring Harb Symp Quant Biol. 1999;64:79\u201386.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1182\/blood-2012-08-450114","volume":"121","author":"I Ferreir\u00f3s-Vidal","year":"2013","unstructured":"Ferreir\u00f3s-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L, et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood. 2013;121:1769\u201382.","journal-title":"Blood"},{"key":"2061_CR12","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.blre.2020.100677","volume":"44","author":"S Vairy","year":"2020","unstructured":"Vairy S, Tran TH. IKZF1 alterations in acute lymphoblastic leukemia: the good, the bad and the ugly. Blood Rev. 2020;44:100677.","journal-title":"Blood Rev"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3324\/haematol.2017.185603","volume":"103","author":"R Marke","year":"2018","unstructured":"Marke R, Leeuwen FN, van, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103:565\u201374.","journal-title":"Haematologica"},{"key":"2061_CR14","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood-2012-08-450627","volume":"121","author":"S Malinge","year":"2013","unstructured":"Malinge S, Thiollier C, Chlon TM, Dor\u00e9 LC, Diebold L, Bluteau O, et al. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood. 2013;121:2440\u201351.","journal-title":"Blood"},{"key":"2061_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ni1314","volume":"7","author":"T Yoshida","year":"2006","unstructured":"Yoshida T, Ng SYM, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol. 2006;7:382\u201391.","journal-title":"Nat Immunol"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1073\/pnas.022412699","volume":"99","author":"RA Lopez","year":"2002","unstructured":"Lopez RA, Schoetz S, DeAngelis K, O\u2019Neill D, Bank A. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci USA. 2002;99:602\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2061_CR17","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1182\/blood-2013-04-494625","volume":"122","author":"KN Rao","year":"2013","unstructured":"Rao KN, Smuda C, Gregory GD, Min B, Brown MA. Ikaros limits basophil development by suppressing C\/EBP-\u03b1 expression. Blood. 2013;122:2572\u201381.","journal-title":"Blood"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2002-05-1336","volume":"101","author":"A Dumortier","year":"2003","unstructured":"Dumortier A, Kirstetter P, Kastner P, Chan S. Ikaros regulates neutrophil differentiation. Blood. 2003;101:2219\u201326.","journal-title":"Blood"},{"key":"2061_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1074-7613(03)00168-7","volume":"19","author":"P Papathanasiou","year":"2003","unstructured":"Papathanasiou P, Perkins AC, Cobb BS, Ferrini R, Sridharan R, Hoyne GF, et al. Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity. 2003;19:131\u201344.","journal-title":"Immunity"},{"key":"2061_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood-2007-07-098202","volume":"111","author":"M Dijon","year":"2008","unstructured":"Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. The role of Ikaros in human erythroid differentiation. Blood. 2008;111:1138\u201346.","journal-title":"Blood"},{"key":"2061_CR21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ijc.23706","volume":"123","author":"A Ruiz","year":"2008","unstructured":"Ruiz A, Williams O, Brady HJM. The Ikaros splice isoform, Ikaros 6, immortalizes murine haematopoietic progenitor cells. Int J Cancer. 2008;123:1240\u20135.","journal-title":"Int J Cancer"},{"key":"2061_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470\u201380.","journal-title":"N Engl J Med"},{"key":"2061_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758\u201364.","journal-title":"Nature"},{"key":"2061_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","volume":"2","author":"TH Tran","year":"2018","unstructured":"Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, et al. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018;2:529\u201333.","journal-title":"Blood Adv"},{"key":"2061_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/ejh.12155","volume":"91","author":"K Tokunaga","year":"2013","unstructured":"Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol. 2013;91:201\u20138.","journal-title":"Eur J Haematol"},{"key":"2061_CR26","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1073\/pnas.0800408105","volume":"105","author":"K Paulsson","year":"2008","unstructured":"Paulsson K, Cazier JB, MacDougall F, Stevens J, Stasevich I, Vrcelj N, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci USA. 2008;105:6708\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2061_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110\u20134.","journal-title":"Nature"},{"key":"2061_CR28","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"I Iacobucci","year":"2009","unstructured":"Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114:2159\u201367.","journal-title":"Blood"},{"key":"2061_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","volume":"123","author":"A van der Veer","year":"2014","unstructured":"van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123:1691\u20138.","journal-title":"Blood"},{"key":"2061_CR30","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122:2622\u20139.","journal-title":"Blood"},{"key":"2061_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters STCJM, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125\u201334.","journal-title":"Lancet Oncol"},{"key":"2061_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/leu.2013.206","volume":"28","author":"L Olsson","year":"2014","unstructured":"Olsson L, Castor A, Behrendtz M, Biloglav A, Forestier E, Paulsson K, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014;28:302\u201310.","journal-title":"Leukemia"},{"key":"2061_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3324\/haematol.2011.056135","volume":"98","author":"P D\u00f6rge","year":"2013","unstructured":"D\u00f6rge P, Meissner B, Zimmermann M, M\u00f6ricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98:428\u201332.","journal-title":"Haematologica"},{"key":"2061_CR34","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1002\/cncr.29579","volume":"121","author":"J Ribera","year":"2015","unstructured":"Ribera J, Morgades M, Zamora L, Montesinos P, G\u00f3mez-Segu\u00ed I, Pratcorona M, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121:3809\u201317.","journal-title":"Cancer"},{"key":"2061_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00277-016-2869-6","volume":"96","author":"W Zhang","year":"2017","unstructured":"Zhang W, Kuang P, Li H, Wang F, Wang Y. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis. Ann Hematol. 2017;96:215\u201325.","journal-title":"Ann Hematol"},{"key":"2061_CR36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3324\/haematol.2015.124321","volume":"100","author":"JDE de Rooij","year":"2015","unstructured":"de Rooij JDE, Beuling E, van den Heuvel-Eibrink MM, Obulkasim A, Baruchel A, Trka J, et al. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia. Haematologica. 2015;100:1151\u20139.","journal-title":"Haematologica"},{"key":"2061_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-020-00972-5","volume":"13","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang X, Li X, Lv Y, Zhu Y, Wang J, et al. The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia. J Hematol Oncol. 2020;13:140.","journal-title":"J Hematol Oncol"},{"key":"2061_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-023-00398-y","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Huang A, Liu L, Qin J, Wang C, Yang M, et al. The clinical impact of IKZF1 mutation in acute myeloid leukemia. Exp Hematol Oncol. 2023;12:33.","journal-title":"Exp Hematol Oncol"},{"key":"2061_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1309","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Cheng W, Zhang Y, Zhang Y, Sun T, Zhu Y, et al. Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia. Clin Transl Med. 2023;13:e1309.","journal-title":"Clin Transl Med"},{"key":"2061_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","volume":"116","author":"C R\u00f6llig","year":"2010","unstructured":"R\u00f6llig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornh\u00e4user M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971\u20138.","journal-title":"Blood"},{"key":"2061_CR41","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","volume":"31","author":"M Schaich","year":"2013","unstructured":"Schaich M, Parmentier S, Kramer M, Illmer T, St\u00f6lzel F, R\u00f6llig C, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31:2094\u2013102.","journal-title":"J Clin Oncol"},{"key":"2061_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdy030","volume":"29","author":"C R\u00f6llig","year":"2018","unstructured":"R\u00f6llig C, Kramer M, Gabrecht M, H\u00e4nel M, Herbst R, Kaiser U, et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973\u20138.","journal-title":"Ann Oncol"},{"key":"2061_CR43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691\u20139.","journal-title":"Lancet Oncol"},{"key":"2061_CR44","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association.","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"2061_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41375-018-0165-2","volume":"33","author":"C Gebhard","year":"2019","unstructured":"Gebhard C, Glatz D, Schwarzfischer L, Wimmer J, Stasik S, Nuetzel M, et al. Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association. Leukemia. 2019;33:26\u201336.","journal-title":"Leukemia"},{"key":"2061_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bdq.2017.12.001","volume":"15","author":"S Stasik","year":"2018","unstructured":"Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornh\u00e4user M, Schetelig J, et al. An optimized targeted next-generation sequencing approach for sensitive detection of single nucleotide variants. Biomol Detect Quantif. 2018;15:6\u201312.","journal-title":"Biomol Detect Quantif"},{"key":"2061_CR47","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","volume":"98","author":"CJ Schwab","year":"2013","unstructured":"Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica. 2013;98:1081\u20138.","journal-title":"Haematologica"},{"key":"2061_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2015.199","volume":"30","author":"JM Boer","year":"2016","unstructured":"Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia. 2016;30:32\u20138.","journal-title":"Leukemia"},{"key":"2061_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25:557\u201360.","journal-title":"Leukemia"},{"key":"2061_CR50","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/leu.2010.99","volume":"24","author":"R J\u00e4ger","year":"2010","unstructured":"J\u00e4ger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010;24:1290\u20138.","journal-title":"Leukemia"},{"key":"2061_CR51","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/ajh.23309","volume":"87","author":"JD Milosevic","year":"2012","unstructured":"Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87:1010\u20136.","journal-title":"Am J Hematol"},{"key":"2061_CR52","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","volume":"33","author":"ML Churchman","year":"2018","unstructured":"Churchman ML, Qian M, te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33:937\u201348.e8.","journal-title":"Cancer Cell"},{"key":"2061_CR53","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1172\/JCI98164","volume":"128","author":"D Boutboul","year":"2018","unstructured":"Boutboul D, Kuehn HS, Van de Wyngaert Z, Niemela JE, Callebaut I, Stoddard J, et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest. 2018;128:3071\u201387.","journal-title":"J Clin Invest"},{"key":"2061_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"2061_CR55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124:536\u201345.","journal-title":"Blood"},{"key":"2061_CR56","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm.4127","volume":"22","author":"J Fang","year":"2016","unstructured":"Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, et al. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nat Med. 2016;22:727\u201334.","journal-title":"Nat Med"},{"key":"2061_CR57","first-page":"237","volume":"2","author":"A Dou","year":"2020","unstructured":"Dou A, Fang J. Cyclosporine broadens the therapeutic potential of lenalidomide in myeloid malignancies. J Cell Immunol. 2020;2:237\u201344.","journal-title":"J Cell Immunol"},{"key":"2061_CR58","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","volume":"36","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, et al. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022;36:2729\u201333.","journal-title":"Leukemia"},{"key":"2061_CR59","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","volume":"3","author":"BJ Aubrey","year":"2022","unstructured":"Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, et al. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022;3:595\u2013613.","journal-title":"Nat Cancer"},{"key":"2061_CR60","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1200\/JCO.2022.40.16_suppl.7025","volume":"40","author":"AH Chourasia","year":"2022","unstructured":"Chourasia AH, Majeski H, Pasis A, Erdman P, Oke A, Hecht D, et al. BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1\/3, for treatment of acute myeloid leukemia (AML) and solid tumors. JCO. 2022;40:7025.","journal-title":"JCO"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02061-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T09:03:58Z","timestamp":1701075838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02061-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02061-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"28 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT is co-owner of Agendix GmbH, a company performing molecular analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}